A growing number of manufacturers are restructuring in response to shrinking margins, supply chain disruptions, and ...

Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Merck is juggling shareholder rebellion and market turbulence ahead of its annual meeting, with the company giving a firm thumbs-down to several investor proposals. This shareholder pushback adds a ...

Listen to this article Mark T. Esser, vice president for vaccines and immune therapies at pharmaceutical giant AstraZeneca, will be the inaugural chief scientific officer and leader of the Paul and ...

Fi AI CEO Ron Insana and Walser Wealth’s Rebecca Walser, join 'Power Lunch' to discuss the market sell-off, opportunities ...

CEOs exercise warrants early, signaling bullish confidence ahead of a key Phase 3 trial data release. Read more here.

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

Perplexity CEO Aravind Srinivas recently took to Reddit to address users’ product complaints and reassure them that the company is not under serious financial pressure. Srinivas seemed to be ...

Notable leaders like Satish Dhawan exemplify such attributes. Zoho CEO Sridhar Vembu’s career advice for managers Effective management is crucial for the success of any organization. A manager ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...